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original report

Chemoradiation and the Role of
Adjuvant Chemotherapy in Lymph
Nodal–Metastatic Cervical Cancer
abstract

Purpose To report the long-term outcome in lymph nodal–metastatic cervical squamous cell cancer after
chemoradiation followed by adjuvant chemotherapy.
Patients and Methods Between 2010 and 2013, five patients were diagnosed with advanced cervical
cancer with clinically involved para-aortic lymph nodes (ie, International Federation of Gynecology and
Obstetrics stage IVB). These patients were treated with concurrent chemoradiation therapy followed by
adjuvant chemotherapy. Concurrent chemoradiation consisted of cisplatin given once per week concomitantly with extended-field radiation therapy followed by high-dose-rate brachytherapy. Adjuvant
chemotherapy comprised four courses of carboplatin and paclitaxel given every three weeks. The primary
outcomes were local and distant failures.
Results None of the patients had local recurrence or distal failure after a minimum follow-up time of 3 years.
Conclusion Adjuvant chemotherapy after chemoradiation has a probable role in the management of lymph
nodal–metastatic cervical cancer.
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INTRODUCTION

PATIENTS AND METHODS

Cervical cancer is an ominous disease when it
presents in locally advanced stages. To date, the
standard of care for locally advanced disease is
pelvic radiotherapy with concurrent cisplatin-based
chemotherapy. However, distant failure remains a
major problem that leads to compromised overall
survival.1 To address this problem, a multinational
randomized trial was conducted in 2002,2 in which
patients received two cycles of adjuvant gemcitabine and cisplatin after completion of definitive
chemoradiation therapy. This treatment led to a
10% improvement in 3-year progression-free
survival. After this, no other trial was conducted
to explore improvements in overall survival.

Patient Case 1

At our university hospital, we treated two patients
in 2010, two in 2012, and one in 2013 with four
cycles of adjuvant carboplatin (area under the
curve [AUC] 5) and paclitaxel (175 mg/m2) after
completion of chemoradiation therapy. Two of
these patients have completed 5 years of followup, two have completed 4 years of follow-up, and
one patient has completed 3 years of follow-up. We
present a short report of five patients who had
lymph nodal–metastatic cervical squamous cell
carcinoma.

A 45-year-old woman presented with locally
advanced squamous cell carcinoma of the cervix. The staging positron emission tomography (PET)/computed tomography (CT) scan
revealed a 6 3 8 cm metabolically active cervical mass with pelvic and para-aortic lymph
nodes that measured more than 1 cm. She
received concurrent cisplatin (40 mg/m 2/week)
and extended-field radiation therapy to the
pelvis and the para-aortic region after threedimensional CT-based planning. The pelvis and
para-aortic field received a dose of 45 Gy at 1.8
Gy/day, followed by a boost to 50.4 Gy to the
para-aortic and pelvic side wall nodes. She then
received three high-dose-rate (HDR) brachytherapy fractions, and an 8-Gy dose was prescribed at point A in each fraction. After
completion of chemoradiation therapy and brachytherapy, she received four cycles of carboplatin and paclitaxel. She completed the whole
treatment in June 2010. The follow-up PET/CT
scan revealed metabolic complete response at
nodal and primary sites. She is free of any disease
at 6 years of follow-up.
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Patient Case 2
In a 43-year-old woman who presented after partial hysterectomy (performed elsewhere), histopathology was consistent with cervical squamous cell
carcinoma, and resection margins were reported
to be positive. Her postoperative CT scan revealed
4-cm residual disease at the vaginal vault with left
parametrial invasion, multiple pelvic nodes, and a
2-cm enhancing left para-aortic node; also, she
had a left pelvic kidney. The treatment plan was as
follows: radiation therapy to the pelvis and paraaortic field with a concurrent cisplatin dose of
40 mg/m2 once per week. Because of previous
partial hysterectomy, brachytherapy could not be
performed, so she received additional boost dose
to the para-aortic nodes to a total dose of 50.4 Gy
and to the pelvic mass to a total dose of 63 Gy at 1.8
Gy/day. After completion of chemoradiation therapy, the patient received four cycles of adjuvant
carboplatin and paclitaxel until June 2010. At 5
years of follow-up, she is free of any disease on
clinical examination and by CT scan performed in
March 2015. Her last follow-up visit was on April
27, 2016.
Patient Case 3
This 48-year-old multiparous woman presented
with biopsy-proven squamous cell carcinoma of
the cervix. The staging CT scan revealed a large
cervical mass as well as pelvic side wall and paraaortic lymphadenopathy. Para-aortic nodes were
measured as more than 2 cm in the short axis. The
planned treatment was chemoradiation therapy to
the pelvis and para-aortic nodes to a total dose of
45 Gy at 1.8 Gy/fraction with cisplatin 40 mg/m2
once per week followed by HDR brachytherapy
to a total dose of 24 Gy in three fractions to point A.
After completion of chemoradiation therapy, the
patient received four cycles of carboplatin and
paclitaxel chemotherapy until January 2012.
She was free of disease at the last follow-up visit
on September 9, 2016.
Patient Case 4
This 54-year-old woman presented with biopsyproven squamous cell carcinoma of the cervix; on
examination under anesthesia, the disease was
staged as IIIB. However, on a staging CT scan of
the chest, abdomen, and pelvis, there were multiple para-aortic nodes that were more than 2 cm
each just below the left renal hilum. The disease
ultimately was staged as IVB squamous cell carcinoma. The planned treatment was extendedfield radiation therapy with concurrent chemotherapy followed by HDR brachytherapy, then four
2

cycles of chemotherapy with carboplatin and paclitaxel. The patient completed treatment in October 2012. She was in remission at the last followup on October 26, 2016.
Patient Case 5
This 62-year-old multiparous woman presented
with cervical biopsy–proven, nonkeratinizing
squamous cell carcinoma. Examination under
anesthesia revealed a 6 3 6 cm cervical mass
fixed to the right pelvic side wall, and a staging
CT scan showed a 3.5 3 7 cm nodal mass just
superior to aortic bifurcation on the right side. The
patient received 45 Gy per 25 fractions of externalbeam radiation therapy to the pelvis and paraaortic field with concurrent cisplatin chemotherapy. In last three cycles of chemotherapy, the dose
of cisplatin had to be reduced to 30/mg/m2 because of grade II hematologic toxicity. This radiation was followed by a boost to the right paraaortic node up to 60 Gy and HDR brachytherapy
at a dose of three fractions of 8 Gy each to point A.
After chemoradiation therapy, the patient received
four cycles of carboplatin and paclitaxel chemotherapy until June 2013. On the PET/CT scan
and a clinical examination at the last follow-up
in June 2016, she was free of any disease.
Radiation Therapy Technique
CT simulation was performed with intravenous
contrast in all patients. For immobilization and
reproducibility of set-up, an alpha cradle vaclock was used in CT simulation. The superior border
of the field was placed at the top of the D12 vertebral
body, and the inferior border was 3 cm inferior to the
caudal-most extent of the disease in the vagina. A
normal saline–soaked gauze piece was put into the
vagina for a negative contrast on imaging. A radioopaque marker was placed at the vaginal introitus,
and a plastic tube was placed in the anal canal for
facilitation of visualization of organs at risk. Lateral
borders were placed 2 cm away from the pelvic
bony margin and 1 cm away from the para-aortic
volume of the nodes, and multileaf collimators were
used to shield normal tissue. Extended pelvis and
para-aortic fields were treated each day with anteroposterior (AP), postero-anterior (PA), and right and
left lateral fields with 18 MV of photon energy. The
radiation planning was performed on Aria 10 planning software (Varian, Palo Alto, CA).
Complete blood counts and serum creatinine were
checked once per week. All of the fields were
treated each day for 5 days per week. Treatmentverification portal films were taken once per week
for accuracy of treatment fields.
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In the last week of external-beam radiotherapy,
first fraction of HDR brachytherapy was instituted with tandem and ovoid applicators. The
brachytherapy procedure was performed under general anesthesia, and careful gauze-piece
packing was performed to displace the rectum
and bladder away from the applicators. The
HDR brachytherapy dose was prescribed at
point A according to International Commission
on Radiation Units and Measurements report 38.
RESULTS AND DISCUSSION
Advanced cervical cancer is a virulent disease,
and the 5-year disease-free survival rate is dismal.
One attempt was made to improve overall survival
in locally advanced cervical cancer in a randomized trial that compared adjuvant cisplatin and
gemcitabine versus no additional chemotherapy.
This trial showed a 10% improvement in the 3-year
progression-free survival, but improvement was at
the cost of slightly increased toxicity seen in the
group that received gemcitabine and cisplatin.3
In a retrospective analysis, Kim et al4 failed to
show a significant difference in survival in patients
who received adjuvant chemotherapy in locally
advanced cervical cancer. In a phase II trial,
Chung et al5 treated patients with extended-field
radiotherapy, concurrent chemotherapy, and brachytherapy followed by two cycles of adjuvant
cisplatin and fluorouracil and demonstrated that
this treatment regimen was feasible. However, we
used extended-field chemoradiation therapy,
HDR brachytherapy, and four cycles of adjuvant
carboplatin and paclitaxel chemotherapy for our
patients; toxicity was acceptable and manageable.
Verghese et al,6 in a phase II trial, used cisplatin
and paclitaxel concurrent with radiotherapy in an
attempt to improve the outcome for locally advanced cervical cancer in Indian women. The trial
failed to show any improvement in response compared with cisplatin alone, and toxicity was greater
in the combination-chemotherapy arm. At our
center, we used single-agent cisplatin concurrent
with radiotherapy followed by the combination of
carboplatin and paclitaxel as adjuvant chemotherapy, and toxicity was less than grade 3 and
manageable.
To date, no randomized trial is available to assess
the impact of carboplatin and paclitaxel as adjuvant combination chemotherapy after chemoradiation therapy in locally advanced disease. A review
by Tangjitgamol et al1 found evidence to use adjuvant chemotherapy after chemoradiation therapy for

3

locally advanced cervical cancer. Recently,
such a trial was initiated in Australia 7 in which
patients with International Federation of Gynecology and Obstetrics (FIGO) stages IB1 to
IVA cervical cancer were randomly assigned to
receive four cycles of adjuvant carboplatin and
paclitaxel or to receive no additional chemotherapy after completion of chemoradiation
therapy. However, we opted to offer this treatment to patients who had FIGO stage IVB
disease (para-aortic lymphadenopathy). Patient case 2 had residual 4-cm cervical cancer
at the vaginal vault, and she received salvage
chemoradiation therapy to the pelvis and paraaortic nodal region. To the pelvic mass, she
received a total of 63 Gy at 1.8 Gy/fraction after
three-dimensional conformal radiotherapy.
Also, she completed her 5 years of follow-up
and is free of any recurrent disease. There is
evidence of adequate local control with radical
radiotherapy of residual disease after inadequate hysterectomy for cervical cancer. 8-10
Petrić Miše et al11 and Jelavić et al12 reported
encouraging results of four adjuvant cycles of
cisplatin and ifosfamide chemotherapy after
completion of concurrent chemoradiotherapy
in an attempt to improve distant-relapse–free
survival. In a randomized trial, Wong et al13
showed improvement in overall survival after
administration of adjuvant chemotherapy with
epirubicin at 90 mg/m2 compared with pelvic
radiotherapy and no additional chemotherapy.
This is a unique report of treatment for patients with
stage IVB disease (para-aortic lymphadenopathy).
In the modern era of oncology, oncologists come
across patients with advanced-stage disease not
infrequently, and the treating oncologist, patients,
and families often fail to understand the prognosis
and goals of treatment, which can lead to a poor
outcome of treatment.14 Should the FIGO stage
IVB disease be segregated into two groups,
patients with widespread distant metastases
and those with para-aortic nodes only. Should
the patients with para-aortic disease only have
a better prognosis, provided they were treated
aggressively. This question may get its answer in
the near future. We hope that the results of the
OUTBACK trial (ClinicalTrials.gov No. NCT01414608)
will be able to resolve the question of whether to use
adjuvant chemotherapy administration in locoregionally advanced cervical cancer.7
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12. Jelavić TB, Miše BP, Strikic A, et al: Adjuvant chemotherapy in locally advanced cervical cancer after treatment with
concomitant chemoradiotherapy: Room for improvement? Anticancer Res 35:4161-4165, 2015
13. Wong LC, Ngan HYS, Cheung ANY, et al: Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol
17:2055-2060, 1999
14. Temel JS, Shaw AT, Greer JA: Challenge of prognostic uncertainity in the modern era of cancer therapeutics. J Clin
Oncol 34:3605-3608, 2016

4

jgo.org JGO – Journal of Global Oncology

Downloaded from ascopubs.org by The Aga Khan University on October 4, 2019 from 058.027.240.066
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.

